BLGO BioLargo Inc (QB)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * DARGAN CHARLES K	2. Issuer Name and Ticker or Trading Symbol BIOLARGO, INC. [ BLGO ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Chief Financial Officer
(Last)          (First)          (Middle) 18851 NE 29TH AVENUE, SUITE 700	3. Date of Earliest Transaction (MM/DD/YYYY) 12/31/2020
(Street) AVENTURA, FL 3318 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase common stock	$0.12	12/31/2020		A		7500		12/31/2020	12/31/2030	Common stock	7500	$0 (1)	3588286 (2)	D

Explanation of Responses:
(1)	This Option was granted to Reporting Person to replace options to purchase an aggregate 30,000 shares of Issuer's common stock that had been issued approximately 10 years ago to compensate Reporting Person for services to the Issuer and had recently expired unexercised due to a discrepancy between the original exercise price and the Issuer's current stock price, pursuant to a plan adopted by the Issuer's Compensation Committee.
(2)	This amount reflects, in addition to the reported option grant, the expiration, during the fourth quarter of 2020, of options to purchase an an aggregate 30,000 shares of common stock.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
DARGAN CHARLES K 18851 NE 29TH AVENUE SUITE 700 AVENTURA, FL 3318			Chief Financial Officer

Signatures
/s/ John R. Browning, Attorney-in-fact		1/4/2021
**Signature of Reporting Person		Date